<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001297'>Stroke</z:hpo> risk in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) using oral <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> is closely related to <z:mp ids='MP_0001914'>bleeding</z:mp> risk </plain></SENT>
<SENT sid="1" pm="."><plain>The HAS-BLED (<z:hpo ids='HP_0000822'>hypertension</z:hpo>, abnormal renal/liver function, <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp> history or predisposition, labile INR [international normalized ratio], elderly, drugs/alcohol concomitantly) <z:mp ids='MP_0001914'>bleeding</z:mp> score has demonstrated usefulness in assessing major <z:mp ids='MP_0001914'>bleeding</z:mp> risk in patients with AF </plain></SENT>
<SENT sid="2" pm="."><plain>However, risk factors for <z:chebi fb="8" ids="10033">warfarin</z:chebi>-associated <z:mp ids='MP_0001914'>bleeding</z:mp> also predict <z:hpo ids='HP_0001297'>stroke</z:hpo> risk in patients with AF </plain></SENT>
<SENT sid="3" pm="."><plain>We tested the usefulness of the HAS-BLED score for predicting both major <z:mp ids='MP_0001914'>bleeding</z:mp> and cardiovascular events in a cohort of anticoagulated patients with AF </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: We recruited 965 consecutive anticoagulated outpatients with permanent or paroxysmal AF who were stabilized for at least 6 months on oral anticoagulation (international normalized ratio, 2.0-3.0) </plain></SENT>
<SENT sid="5" pm="."><plain>Medical history and HAS-BLED score were assessed </plain></SENT>
<SENT sid="6" pm="."><plain>Cox regression models were used to determine the association between clinical risk factors and <z:mp ids='MP_0001914'>bleeding</z:mp> episodes, adverse cardiovascular events, and mortality </plain></SENT>
<SENT sid="7" pm="."><plain>The median HAS-BLED score was 2 (range, 0-6; 29% with a score ≥3 [ie, high risk]) </plain></SENT>
<SENT sid="8" pm="."><plain>Median follow-up was 861 days (range, 718-1016 days) </plain></SENT>
<SENT sid="9" pm="."><plain>Independent predictors for major <z:mp ids='MP_0001914'>bleeding</z:mp> were age ≥75 years (hazard ratio [HR], 1.74; 95% CI, 1.05-2.87; P=0.030), male sex (HR, 1.70; 95% CI, 1.03-2.80; P=0.036), <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> (HR, 2.12; 95% CI, 1.20-3.73; P=0.010), previous <z:mp ids='MP_0001914'>bleeding</z:mp> episode (HR, 6.00; 95% CI, 3.73-9.67; P&lt;0.001), current alcohol consumption (HR, 2.28; 95% CI, 1.03-5.06; P=0.043), and concomitant malignant disease (HR, 2.17; 95% CI, 1.13-4.18; P=0.020) </plain></SENT>
<SENT sid="10" pm="."><plain>Independent predictors for adverse cardiovascular events were age &gt;75 years (HR, 2.20; 95% CI, 1.40-3.46; P=0.001), <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HR, 1.78; 95% CI, 1.20-2.86; P=0.001), and previous <z:hpo ids='HP_0001297'>stroke</z:hpo> (HR, 1.85; 95% CI, 1.20-2.86; P&lt;0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>The HAS-BLED score was highly predictive for major <z:mp ids='MP_0001914'>bleeding</z:mp> events (HR, 2.04; 95% CI, 1.68-2.49; P&lt;0.001) and adverse cardiovascular events (HR, 1.51; 95% CI, 1.27-1.81; P&lt;0.001) </plain></SENT>
<SENT sid="12" pm="."><plain>The incidence of both <z:mp ids='MP_0001914'>bleeding</z:mp> and adverse cardiovascular events was higher as HAS-BLED score increased, and crude <z:mp ids='MP_0001914'>bleeding</z:mp> rates only exceeded thrombotic events at a HAS-BLED score &gt;3 </plain></SENT>
<SENT sid="13" pm="."><plain>The HAS-BLED score also predicted <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality (HR, 1.68; 95% CI, 1.40-2.01; P&lt;0.001) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: The HAS-BLED score not only is useful in the assessment of <z:mp ids='MP_0001914'>bleeding</z:mp> risk, but also shows some predictive value for cardiovascular events and mortality in anticoagulated patients with AF, consistent with the relationship between <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="15" pm="."><plain>Nonetheless, the HAS-BLED score has been designed for predicting <z:mp ids='MP_0001914'>bleeding</z:mp> risk rather than thrombotic events per se, and specific risk scores for cardiovascular events and mortality should be applied for these events </plain></SENT>
</text></document>